MediWound (MDWD) Q2 2025: NexoBrid US Sales Jump 52% as Manufacturing Scale-Up Nears Completion

August 14, 2025 | By EarningsIQ Research

MediWound’s Q2 2025 results highlight robust NexoBrid US sales growth and progress on its manufacturing expansion, but rising R&D spend and operational losses underscore the cost of advancing late-stage clinical programs. With global wound care partnerships deepening and regulatory milestones approaching, the next twelve months will test MediWound’s ability to convert pipeline momentum into sustainable commercial gains.

Summary

• NexoBrid US Traction: US partner Vericel reported 52% year-over-year NexoBrid revenue growth, confirming expanding hospital adoption.
• Pipeline and Partnerships: Escarex Phase III trial enrollment and new collaborations with Convatec and SCT broaden clinical validation.
• Manufacturing Inflection: Facility scale-up on track for year-end, with regulatory approvals to unlock output and address unmet demand.

Performance Analysis

MediWound’s Q2 2025 financials reflect a business in clinical and commercial transition. Revenue climbed to $5.7 million, up from $5.1 million a year ago, driven by higher product sales and a more favorable mix. Gross margin expanded to 23.5% from 8.8% as product sales outpaced lower-margin development revenue. However, operating expenses surged—R&D doubled to $3.5 million as the Escarex Phase III trial ramped, and SG&A rose to $3.6 million, mainly from increased share-based compensation.

Operating loss widened to $5.7 million, and net loss more than doubled to $13.3 million, largely due to a $6.6 million non-cash warrant revaluation. Cash burn was significant with $11.9 million used in operations and capex, though $32.9 million remains on hand, bolstered by warrant exercises. Adjusted EBITDA loss increased to $4.5 million, reflecting the heavy investment phase. The company’s first half revenue was slightly down year-over-year, as BARDA-funded development revenue tapered with the NexoBrid R&D program nearing completion.

• Gross Margin Recovery: Higher product sales and improved mix drove a notable margin rebound, partially offsetting R&D pressure.
• Escarex Investment: Phase III trial spending is the primary driver of increased R&D, with European site activations to further elevate costs in H2.
• Cash Position: $32.9 million in cash plus warrant proceeds offer operational runway, but ongoing losses will test capital discipline.

Overall, MediWound’s financials signal a company scaling for future growth but still in a high-burn, pre-commercial inflection period for its next wave of products.

Executive Commentary

Strategic Positioning

1. NexoBrid Commercial Expansion

NexoBrid, enzymatic burn debridement therapy, is gaining traction in the US, with partner Vericel reporting 52% revenue growth and more hospitals adopting the product. However, global demand is outpacing current manufacturing capacity, with zero inventory and all output sold immediately. The ongoing facility expansion is critical, as regulatory approvals in Europe and the US—expected in the first and second halves of 2026, respectively—will determine the timing of revenue ramp-up.

2. Escarex Clinical Momentum and Validation

Escarex, late-stage enzymatic debridement for chronic wounds, is advancing through its pivotal Phase III trial for venous leg ulcers (VLU), with 40 sites targeted across the US and Europe. New collaborations with Convatec and SCT, alongside leading partners like Essity and Solventum, demonstrate broad industry buy-in and aim to establish Escarex as a universally compatible adjunct to standard care. Publication of a post-hoc Phase II analysis in a leading journal further validates the trial’s wound bed preparation endpoint.

3. Government and Defense Partnerships

BARDA, Biomedical Advanced Research and Development Authority, and the Department of Defense continue to fund NexoBrid manufacturing and development, including a $3.6 million DoD award for a room temperature stable formulation. BARDA’s recent RFP signals a decade-long US government stockpiling and trauma contract, which could anchor long-term revenue and manufacturing stability.

4. Manufacturing Scale and Regulatory Pathways

Facility commissioning remains on track, with regulatory submissions to EMA and FDA slated for late 2025. Approval timelines are staggered by region, with Europe likely to unlock expanded supply first. The company is also planning US-based manufacturing with BARDA support, aiming to reduce geopolitical risk and secure domestic supply.

5. Diversified Clinical and Commercial Ecosystem

By integrating multiple leading wound care products and partners into its pivotal trials, MediWound is positioning Escarex as a flexible, evidence-based solution, agnostic to physician preference or standard-of-care variations. This ecosystem approach may accelerate adoption post-approval and insulate the product from reimbursement or competitive shifts.

Key Considerations

MediWound is executing a multi-pronged strategy that hinges on clinical validation, manufacturing scale, and deepening industry partnerships. The next year is pivotal for converting pipeline progress into commercial growth.

Key Considerations:

• Regulatory Milestones: Timely EMA and FDA approvals for the new facility are required to unlock NexoBrid’s full commercial potential.
• Clinical Data and Publications: Additional peer-reviewed data and head-to-head trials (versus collagenase) are planned to further validate Escarex and build market appetite ahead of launch.
• Government Backing: BARDA and DoD funding de-risk manufacturing expansion and product development, but future contract terms and political priorities remain variable.
• Reimbursement Policy Shifts: Proposed Medicare changes for skin substitutes and wound care may favor evidence-based products like Escarex, but could disrupt legacy product utilization patterns.
• Cash Runway: While cash plus warrant proceeds offer flexibility, continued losses and rising R&D spend will require careful capital management if regulatory or commercial timelines slip.

Risks

Execution risk is high as MediWound juggles late-stage clinical trials, facility validation, and regulatory submissions across multiple geographies. Any delays in EMA or FDA approvals could constrain NexoBrid sales and prolong cash burn. Competitive trials for wound care patients, evolving reimbursement rules, and reliance on government funding add further uncertainty. Investors should monitor for regulatory, operational, and funding milestones over the next four quarters.

Forward Outlook

For Q3 and Q4 2025, MediWound reiterated:

• Full-year revenue guidance of $24 million, with H2 growth primarily from development services, not NexoBrid sales.
• Completion of manufacturing facility commissioning by year-end, with regulatory submissions to follow.

For full-year 2025, management maintained guidance and expects:

• Escarex Phase III enrollment to remain on track, with interim sample size assessment by mid-2026.
• Continued expansion of US and European clinical trial sites and new data releases at major wound care conferences.

Management highlighted that operating expenses will rise in H2 as European trial sites activate, and that EMA approval is expected in the first half of 2026, with FDA to follow in the second half.

Takeaways

MediWound’s quarter underscores a high-stakes transition phase:

• NexoBrid US Growth: Commercial adoption is outpacing supply, but manufacturing expansion is the gating factor for further revenue gains.
• Pipeline Validation: Escarex’s clinical progress and ecosystem partnerships position it for broad adoption, provided pivotal data and regulatory milestones are achieved.
• Capital Stewardship: Cash reserves and warrant proceeds offer near-term runway, but execution risk remains high until new approvals and commercial inflection points are reached.

Conclusion

MediWound is at a critical juncture, with commercial traction for NexoBrid and a robust late-stage pipeline, but must deliver on manufacturing scale-up and pivotal trial execution to realize its full growth potential. The next twelve months will determine whether clinical and operational milestones translate into sustainable commercial momentum.

Industry Read-Through

MediWound’s results provide a window into the evolving wound care landscape, where evidence-based products, manufacturing resilience, and government partnerships are increasingly central. The growing emphasis on robust clinical data and universal compatibility in pivotal trials signals a shift toward higher regulatory and payer scrutiny for advanced wound care products. Companies with proven clinical outcomes and manufacturing agility are likely to gain share as reimbursement reforms and supply chain localization accelerate across the sector.

MDWD Healthcare Biotechnology Wound Care Government Contracts Manufacturing Clinical Trials Reimbursement